MS FIRST - utilising a longitudinal, prospective, comparative drug safety module for use in everyday MS clinical practice to evaluate and track incidence and characteristics of safety outcomes in MS patients on therapy over the long term

J. Haartsen, T. Spelman, J. Baker, S. Agland, J. Lechner-Scott, T. Burke, S. Vucic, L. Rath, O. Skibina, M. Toubia, M. Slee, B. Taylor, S. Mac Gregor, A. M. Oconnell, M. Barnett, S. Baker, M. Sharma, S. Hodgkinson, S. Walters, A. Kermode & 8 others W. Hayes, E. Butler, N. Sheuy, C. Shaw, R. Portley, T. Hardy, I. L. Tan, H. Butzkueven

Research output: Contribution to journalAbstract/Meeting Abstract

17 Citations (Scopus)
Original languageEnglish
Pages (from-to)403-404
Number of pages2
JournalMultiple Sclerosis Journal
Volume23
Publication statusPublished - Oct 2017
Event7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) - Paris, France
Duration: 25 Oct 201728 Oct 2017

Cite this

Haartsen, J. ; Spelman, T. ; Baker, J. ; Agland, S. ; Lechner-Scott, J. ; Burke, T. ; Vucic, S. ; Rath, L. ; Skibina, O. ; Toubia, M. ; Slee, M. ; Taylor, B. ; Mac Gregor, S. ; Oconnell, A. M. ; Barnett, M. ; Baker, S. ; Sharma, M. ; Hodgkinson, S. ; Walters, S. ; Kermode, A. ; Hayes, W. ; Butler, E. ; Sheuy, N. ; Shaw, C. ; Portley, R. ; Hardy, T. ; Tan, I. L. ; Butzkueven, H. / MS FIRST - utilising a longitudinal, prospective, comparative drug safety module for use in everyday MS clinical practice to evaluate and track incidence and characteristics of safety outcomes in MS patients on therapy over the long term. In: Multiple Sclerosis Journal. 2017 ; Vol. 23. pp. 403-404.
@article{9e20f70df45242398aea2c1b5b156194,
title = "MS FIRST - utilising a longitudinal, prospective, comparative drug safety module for use in everyday MS clinical practice to evaluate and track incidence and characteristics of safety outcomes in MS patients on therapy over the long term",
author = "J. Haartsen and T. Spelman and J. Baker and S. Agland and J. Lechner-Scott and T. Burke and S. Vucic and L. Rath and O. Skibina and M. Toubia and M. Slee and B. Taylor and {Mac Gregor}, S. and Oconnell, {A. M.} and M. Barnett and S. Baker and M. Sharma and S. Hodgkinson and S. Walters and A. Kermode and W. Hayes and E. Butler and N. Sheuy and C. Shaw and R. Portley and T. Hardy and Tan, {I. L.} and H. Butzkueven",
year = "2017",
month = "10",
language = "English",
volume = "23",
pages = "403--404",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",

}

Haartsen, J, Spelman, T, Baker, J, Agland, S, Lechner-Scott, J, Burke, T, Vucic, S, Rath, L, Skibina, O, Toubia, M, Slee, M, Taylor, B, Mac Gregor, S, Oconnell, AM, Barnett, M, Baker, S, Sharma, M, Hodgkinson, S, Walters, S, Kermode, A, Hayes, W, Butler, E, Sheuy, N, Shaw, C, Portley, R, Hardy, T, Tan, IL & Butzkueven, H 2017, 'MS FIRST - utilising a longitudinal, prospective, comparative drug safety module for use in everyday MS clinical practice to evaluate and track incidence and characteristics of safety outcomes in MS patients on therapy over the long term' Multiple Sclerosis Journal, vol. 23, pp. 403-404.

MS FIRST - utilising a longitudinal, prospective, comparative drug safety module for use in everyday MS clinical practice to evaluate and track incidence and characteristics of safety outcomes in MS patients on therapy over the long term. / Haartsen, J.; Spelman, T.; Baker, J.; Agland, S.; Lechner-Scott, J.; Burke, T.; Vucic, S.; Rath, L.; Skibina, O.; Toubia, M.; Slee, M.; Taylor, B.; Mac Gregor, S.; Oconnell, A. M.; Barnett, M.; Baker, S.; Sharma, M.; Hodgkinson, S.; Walters, S.; Kermode, A.; Hayes, W.; Butler, E.; Sheuy, N.; Shaw, C.; Portley, R.; Hardy, T.; Tan, I. L.; Butzkueven, H.

In: Multiple Sclerosis Journal, Vol. 23, 10.2017, p. 403-404.

Research output: Contribution to journalAbstract/Meeting Abstract

TY - JOUR

T1 - MS FIRST - utilising a longitudinal, prospective, comparative drug safety module for use in everyday MS clinical practice to evaluate and track incidence and characteristics of safety outcomes in MS patients on therapy over the long term

AU - Haartsen, J.

AU - Spelman, T.

AU - Baker, J.

AU - Agland, S.

AU - Lechner-Scott, J.

AU - Burke, T.

AU - Vucic, S.

AU - Rath, L.

AU - Skibina, O.

AU - Toubia, M.

AU - Slee, M.

AU - Taylor, B.

AU - Mac Gregor, S.

AU - Oconnell, A. M.

AU - Barnett, M.

AU - Baker, S.

AU - Sharma, M.

AU - Hodgkinson, S.

AU - Walters, S.

AU - Kermode, A.

AU - Hayes, W.

AU - Butler, E.

AU - Sheuy, N.

AU - Shaw, C.

AU - Portley, R.

AU - Hardy, T.

AU - Tan, I. L.

AU - Butzkueven, H.

PY - 2017/10

Y1 - 2017/10

M3 - Abstract/Meeting Abstract

VL - 23

SP - 403

EP - 404

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

ER -